Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition

Journal: Nature Medicine

Published: 2018-05-28

DOI: 10.1038/s41591-018-0022-x

Affiliations: 21

Authors: 38

Go to article
Institutions FC
Department of Medical Oncology, DFCI, United States of America (USA) 0.25
Section of Hematology/Oncology, UChicago, United States of America (USA) 0.16
NantOmics, LLC, United States of America (USA) 0.13
Cancer Area, Broad Institute, United States of America (USA) 0.13
Department of Gastroenterological Surgery, Kumamoto University, Japan 0.08
Department of Biomolecular Sciences, UNIURB, Italy 0.05
Department of Surgery and Science, Kyushu University, Japan 0.03
Sanofi-Aventis, United States of America (USA) 0.03
Department of Biochemistry and Molecular Biology, MUSC, United States of America (USA) 0.03
Cancer Institute, JFCR, Japan 0.03
Harvard Medical School (HMS), United States of America (USA) 0.03
Surface Oncology, United States of America (USA) 0.01
NYU Langone Medical Center (NYULMC), United States of America (USA) 0.01
Department of Medicine (DOM), BWH, United States of America (USA) 0.01
Department of Medicine, Penn, United States of America (USA) 0.01
Department of Genetics, Penn, United States of America (USA) 0.01
Division of Gastroenterology (GI), Penn, United States of America (USA) 0.01
Department of Cancer Biology, DFCI, United States of America (USA) 0.01

Return